These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 19586080)

  • 1. Pharmaceutical risk-sharing agreements.
    Gandjour A
    Pharmacoeconomics; 2009; 27(5):431-2. PubMed ID: 19586080
    [No Abstract]   [Full Text] [Related]  

  • 2. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Risk-sharing schemes: a new paradigm in adopting innovative pharmaceuticals].
    Hammerman A; Greenberg D
    Harefuah; 2012 Jun; 151(6):364-7, 376. PubMed ID: 22991869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The simple economics of risk-sharing agreements between the NHS and the pharmaceutical industry.
    Barros PP
    Health Econ; 2011 Apr; 20(4):461-70. PubMed ID: 21394816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmaceutical risk-sharing agreements.
    Cook JP; Vernon JA; Manning R
    Pharmacoeconomics; 2008; 26(7):551-6. PubMed ID: 18563946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Italian risk-sharing agreements on drugs: are they worthwhile?
    Garattini L; Curto A; van de Vooren K
    Eur J Health Econ; 2015 Jan; 16(1):1-3. PubMed ID: 24728513
    [No Abstract]   [Full Text] [Related]  

  • 7. Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement.
    Neumann PJ; Chambers JD; Simon F; Meckley LM
    Health Aff (Millwood); 2011 Dec; 30(12):2329-37. PubMed ID: 22147861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of two pharmaceutical risk-sharing agreements on pricing, promotion, and net health benefits.
    Zaric GS; Xie B
    Value Health; 2009; 12(5):838-45. PubMed ID: 19490563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.
    Adamski J; Godman B; Ofierska-Sujkowska G; Osińska B; Herholz H; Wendykowska K; Laius O; Jan S; Sermet C; Zara C; Kalaba M; Gustafsson R; Garuolienè K; Haycox A; Garattini S; Gustafsson LL
    BMC Health Serv Res; 2010 Jun; 10():153. PubMed ID: 20529296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. When are Pharmaceuticals Priced Fairly? An Alternative Risk-Sharing Model for Pharmaceutical Pricing.
    Balderrama F; Schwartz LJ; Longo CJ
    Health Care Anal; 2020 Jun; 28(2):121-136. PubMed ID: 32232611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The current performance-linked and risk sharing agreement scene in the Spanish region of Catalonia.
    Darbà J; Ascanio M
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):743-748. PubMed ID: 30821532
    [No Abstract]   [Full Text] [Related]  

  • 12. [Innovative agreements with the pharmaceutical industry: "pay for performance"].
    Badia X; Prior M
    Farm Hosp; 2010; 34(2):53-5. PubMed ID: 20207566
    [No Abstract]   [Full Text] [Related]  

  • 13. Aligning incentives for value-based health care.
    Doliveux R
    Health Aff (Millwood); 2012 Apr; 31(4):883; author reply 884. PubMed ID: 22492906
    [No Abstract]   [Full Text] [Related]  

  • 14. Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products.
    Towse A; Garrison LP
    Pharmacoeconomics; 2010; 28(2):93-102. PubMed ID: 20085386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of managed entry agreements on pharmaceutical prices.
    Gamba S; Pertile P; Vogler S
    Health Econ; 2020 Oct; 29 Suppl 1():47-62. PubMed ID: 32628324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmaceutical Pricing and Market Access Outlook Europe 2010-HealthNetwork Communications' fourth annual conference. 24-25 March 2010, London, UK.
    Ogbighele E
    IDrugs; 2010 May; 13(5):317-20. PubMed ID: 20432188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk sharing or risk shifting? On the development of patient access schemes in the process of updating the national list of health services in Israel.
    Triki N; Ash N; Porath A; Birnbaum Y; Greenberg D; Hammerman A
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):749-753. PubMed ID: 31825682
    [No Abstract]   [Full Text] [Related]  

  • 18. Risk-sharing agreements for innovative drugs: a new solution to old problems?
    de Pouvourville G
    Eur J Health Econ; 2006 Sep; 7(3):155-7. PubMed ID: 16912890
    [No Abstract]   [Full Text] [Related]  

  • 19. European pharmaceutical pricing and reimbursement conference.
    Ehreth J; Williams D
    Expert Rev Pharmacoecon Outcomes Res; 2009 Feb; 9(1):37-9. PubMed ID: 19371177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should health authorities offer risk-sharing contracts to pharmaceutical firms? A theoretical approach.
    Antonanzas F; Juarez-Castello C; Rodriguez-Ibeas R
    Health Econ Policy Law; 2011 Jul; 6(3):391-403. PubMed ID: 21338542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.